GlassScriptPhysician profile
Rene B Mackay
NPI 1285652990
$2,726.28
in general payments reported to CMS, 2019-2025
29 companies · $656 in 2025
The $656 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $127 · 2021: $229 · 2022: $509 · 2023: $381 · 2024: $476 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419 · Education: $95.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.19 |
| Education | $95.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $425.08 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Horizon Therapeutics Plc | $301.95 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $252.41 | 2021-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $243.66 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $181.89 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $171.84 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $141.35 | 2019-2023 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $132.22 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $129.27 | 2021-2025 | Terlivaz |
| Akebia Therapeutics INC | $98.10 | 2019-2024 | Vafseo |
| Calliditas Therapeutics US INC. | $95.95 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $79.53 | 2021-2023 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.74 | 2019 | |
| Novo Nordisk INC | $52.18 | 2023-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $47.90 | 2022-2023 | Veltassa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $47.38 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $43.37 | 2022-2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $23.08 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.77 | 2019-2020 | |
| Ardelyx, INC. | $22.56 | 2024 | Ibsrela |
| Lilly USA, LLC | $21.75 | 2024 | Jardiance |
| Genzyme Corporation | $18.41 | 2023 | |
| Scpharmaceuticals INC. | $17.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.65 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $15.95 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $14.57 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.09 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.00 | 2022 | |
| Chiesi USA, INC. | $13.97 | 2025 | Elfabrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Mackay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.